|
1
|
Gayle S, Landrette S, Beeharry N, Conrad
C, Hernandez M, Beckett P, Ferguson SM, Mandelkern T, Zheng M, Xu
T, et al: Identification of apilimod as a first-in-class PIKfyve
kinase inhibitor for treatment of B-cell non-hodgkin lymphoma.
Blood. 129:1768–1778. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Riley SN: Investigating the multivariate
nature of NHL player performance with structural equation modeling.
PLoS one. 12:e01843462017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yin H, Miao X, Wu Y, Wei Y, Zong G, Yang
S, Chen X, Zheng G, Zhu X, Guo Y, et al: The role of the chaperonin
containing t-complex polypeptide 1, subunit 8 (CCT8) in B-cell
non-hodgkin's lymphoma. Leuk Res. 45:59–67. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu X, Miao X, Wu Y, Li C, Guo Y, Liu Y,
Chen Y, Lu X, Wang Y and He S: ENO1 promotes tumor proliferation
and cell adhesion mediated drug resistance (CAM-DR) in
non-hodgkin's lymphomas. Exp Cell Res. 335:216–223. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hazlehurst LA and Dalton WS: Mechanisms
associated with cell adhesion mediated drug resistance (CAM-DR) in
hematopoietic malignancies. Cancer Metastasis Rev. 20:43–50. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Landowski TH, Olashaw NE, Agrawal D and
Dalton WS: Cell adhesion-mediated drug resistance (CAM-DR) is
associated with activation of NF-kappa B (RelB/p50) in myeloma
cells. Oncogene. 22:2417–2421. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miao X, Xu X, Wu Y, Zhu X, Chen X, Li C,
Lu X, Chen Y, Liu Y, Huang J, et al: Overexpression of TRIP6
promotes tumor proliferation and reverses cell adhesion-mediated
drug resistance (CAM-DR) via regulating nuclear p27(Kip1)
expression in non-hodgkin's lymphoma. Tumour Biol. 37:1369–1378.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakagawa Y, Nakayama H, Nagata M, Yoshida
R, Kawahara K, Hirosue A, Tanaka T, Yuno A, Matsuoka Y, Kojima T,
et al: Overexpression of fibronectin confers cell adhesion-mediated
drug resistance (CAM-DR) against 5-FU in oral squamous cell
carcinoma cells. Int J Oncol. 44:1376–1384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hou X, Li T, Ren Z and Liu Y: Novel
BRCA2-interacting protein, LIMD1, is essential for the centrosome
localization of BRCA2 in esophageal cancer cell. Oncol Res.
24:247–253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sharp TV, Al-Attar A, Foxler DE, Ding L,
de A Vallim TQ, Zhang Y, Nijmeh HS, Webb TM, Nicholson AG, Zhang Q,
et al: The chromosome 3p21.3-encoded gene, LIMD1, is a critical
tumor suppressor involved in human lung cancer development. Proc
Natl Acad Sci USA. 105:19932–19937. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Spendlove I, Al-Attar A, Watherstone O,
Webb TM, Ellis IO, Longmore GD and Sharp TV: Differential
subcellular localisation of the tumour suppressor protein LIMD1 in
breast cancer correlates with patient survival. Int J Cancer.
123:2247–2253. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huggins CJ, Gill M and Andrulis IL:
Identification of rare variants in the hLIMD1 gene in breast
cancer. Cancer Genet Cytogenet. 178:36–41. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kiss H, Kedra D, Yang Y, Kost-Alimova M,
Kiss C, O'Brien KP, Fransson I, Klein G, Imreh S and Dumanski JP: A
novel gene containing LIM domains (LIMD1) is located within the
common eliminated region 1 (C3CER1) in 3p21.3. Hum Genet.
105:552–559. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huggins CJ and Andrulis IL: Cell cycle
regulated phosphorylation of LIMD1 in cell lines and expression in
human breast cancers. Cancer Lett. 267:55–66. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mayank AK, Sharma S, Deshwal RK and Lal
SK: LIMD1 antagonizes E2F1 activity and cell cycle progression by
enhancing Rb function in cancer cells. Cell Biol Int. 38:809–817.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hang Q, Fei M, Hou S, Ni Q, Lu C, Zhang G,
Gong P, Guan C, Huang X and He S: Expression of Spy1 protein in
human non-Hodgkin's lymphomas is correlated with phosphorylation of
p27 Kip1 on Thr187 and cell proliferation. Med Oncol. 29:3504–3514.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hazlehurst LA, Damiano JS, Buyuksal I,
Pledger WJ and Dalton WS: Adhesion to fibronectin via beta1
integrins regulates p27kip1 levels and contributes to cell adhesion
mediated drug resistance (CAM-DR). Oncogene. 19:4319–4327. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sarkar S, Maiti GP, Jha J, Biswas J, Roy
A, Roychoudhury S, Sharp T and Panda CK: Reduction of proliferation
and induction of apoptosis are associated with shrinkage of head
and neck squamous cell carcinoma due to neoadjuvant chemotherapy.
Asian Pac J Cancer Prev. 14:6419–6425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang X, Wang Y, Nan X, He S, Xu X, Zhu X,
Tang J, Yang X, Yao L, Wang X and Cheng C: The role of the orphan G
protein-coupled receptor 37 (GPR37) in multiple myeloma cells. Leuk
Res. 38:225–235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Damiano JS, Cress AE, Hazlehurst LA, Shtil
AA and Dalton WS: Cell adhesion mediated drug resistance (CAM-DR):
Role of integrins and resistance to apoptosis in human myeloma cell
lines. Blood. 93:1658–1667. 1999.PubMed/NCBI
|
|
21
|
Chen Z, Zhu X, Xie T, Xie J, Quo K and Liu
X: Drug resistance reversed by silencing LIM domain-containing
protein 1 expression in colorectal carcinoma. Oncol Lett.
8:795–798. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A,
Roy B, Roychoudhury S and Panda CK: Alterations of 3p21.31 tumor
suppressor genes in head and neck squamous cell carcinoma:
Correlation with progression and prognosis. Int J Cancer.
123:2594–2604. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghosh S, Ghosh A, Maiti GP, Mukherjee N,
Dutta S, Roy A, Roychoudhury S and Panda CK: LIMD1 is more
frequently altered than RB1 in head and neck squamous cell
carcinoma: Clinical and prognostic implications. Mol Cancer.
9:582010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang J, Ji L, Wang Y, Huang Y, Yin H, He
Y, Liu J, Miao X, Wu Y, Xu X, et al: Cell adhesion down-regulates
the expression of vacuolar protein sorting 4B (VPS4B) and
contributes to drug resistance in multiple myeloma cells. Int J
Hematol. 102:25–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ouyang Y, Zhong F, Wang Q, Ding L, Zhang
P, Chen L, Wang Y and Cheng C: DIXDC1 promotes tumor proliferation
and cell adhesion mediated drug resistance (CAM-DR) via enhancing
p-Akt in Non-Hodgkin's lymphomas. Leuk Res. 50:104–111. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Balsas P, Palomero J, Eguileor Á,
Rodríguez ML, Vegliante MC, Planas-Rigol E, Sureda-Gómez M, Cid MC,
Campo E and Amador V: SOX11 promotes tumor protective
microenvironment interactions through CXCR4 and FAK regulation in
mantle cell lymphoma. Blood. 130:501–513. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bjorklund CC, Baladandayuthapani V, Lin
HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang
M, et al: Evidence of a role for CD44 and cell adhesion in
mediating resistance to lenalidomide in multiple myeloma:
Therapeutic implications. Leukemia. 28:373–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsubaki M, Takeda T, Yoshizumi M, Ueda E,
Itoh T, Imano M, Satou T and Nishida S: RANK-RANKL interactions are
involved in cell adhesion-mediated drug resistance in multiple
myeloma cell lines. Tumour Biol. 37:9099–9110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Waldschmidt JM, Simon A, Wider D, Müller
SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK,
et al: CXCL12 and CXCR7 are relevant targets to reverse cell
adhesion-mediated drug resistance in multiple myeloma. Br J
Haematol. 179:36–49. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Foxler DE, James V, Shelton SJ, Vallim TQ,
Shaw PE and Sharp TV: PU.1 is a major transcriptional activator of
the tumour suppressor gene LIMD1. FEBS Lett. 585:1089–1096. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao MK, Wang Y, Murphy K, Yi J, Beckerle
MC and Gilmore TD: LIM domain-containing protein trip6 can act as a
coactivator for the v-Rel transcription factor. Gene Exp.
8:207–217. 1999.
|
